BCL2 genotypes and prostate cancer survival.

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• The B-cell lymphoma 2 (BCL2) gene plays a crucial role in cancer development and progression.
• A specific single-nucleotide polymorphism (SNP), c.-938C>A (rs2279115), in the BCL2 gene's P2 promoter has been associated with cancer outcomes.
• Understanding the impact of this genetic variation is important for predicting patient prognosis.

Purpose of the Study:

• To investigate the association between BCL2-938C>A genotypes and mortality in prostate cancer.
• To determine if the rs2279115 polymorphism influences cancer-specific survival (CSS) and overall survival (OS) in prostate cancer patients.

Main Methods:

• The study utilized data from the prospective PROCAGENE cohort, including 702 prostate cancer patients.
• Genotyping for the BCL2-938C>A (rs2279115) polymorphism was performed.
• Survival analysis was conducted using univariate and multivariate Cox regression models, adjusting for clinical factors.

Main Results:

• Over a median follow-up of 92 months, 17.1% of patients died.
• The homozygous CC genotype for BCL2-938C>A was significantly associated with reduced CSS and OS in univariate analysis.
• In multivariate analysis, the CC genotype remained an independent predictor of poor CSS and OS, even after adjusting for age, risk group, and androgen deprivation therapy.

Conclusions:

• The homozygous BCL2-938 CC genotype is a significant predictor of poorer overall survival and cancer-specific survival in prostate cancer patients.
• This genetic marker may contribute to understanding individual patient prognosis and guiding treatment strategies.
• Further research could explore the functional mechanisms underlying this association.